Jaka jest cena za Organicell Regenerative Medicine, Inc. (OCEL)

Cena za Organicell Regenerative Medicine, Inc. (OCEL) wynosi $1.77

Jaka jest kapitalizacja rynkowa dla Organicell Regenerative Medicine, Inc. (OCEL)

Kapitalizacja rynkowa dla Organicell Regenerative Medicine, Inc. (OCEL) wynosi $12.89M

Zyski Organicell Regenerative Medicine, Inc. (OCEL)

Organicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering biological therapies for degenerative conditions. Their primary investigational product is Zofin, an acellular biological treatment sourced from perinatal material. This therapeutic is specifically processed to preserve its inherent microRNAs, without the inclusion of any artificial additives or diluents. Zofin is currently undergoing Phase I/II clinical evaluation for its efficacy against COVID-19. Beyond its core drug development, Organicell also offers independent educational, promotional, and marketing solutions to various healthcare sectors, including medical, anti-aging, and regenerative service providers. The company maintains key research collaborations: one with the Centers for Disease Control and Prevention (CDC) to explore Zofin's anti-inflammatory and anti-infective capabilities in experimental influenza models, and another with Oklahoma State University to assess Zofin's potential in treating severe respiratory illnesses stemming from viruses with pandemic risk. Founded in 2011, this Miami, Florida-based company initially operated as Biotech Products Services and Research, Inc. It adopted its current name, Organicell Regenerative Medicine, Inc., in June 2018.

Rok	Zyski	Zmień
Za mało danych dla podanych dat.

Rok

Zyski

Zmień

Za mało danych dla podanych dat.

Firma	Zyski	Różnica w zyskach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR

Firma

Zyski

Różnica w zyskach

Kraj